Category : Hip Preservation and Hip Arthroscopy / Orthopaedics
The aim of this study was to compare the efficacy and safety profiles of acemetacin and indomethacin for prophylaxis of heterotopic ossification (HO) following hip arthroscopy. While indomethacin is a well-established agent, evidence on acemetacin remains limited. This retrospective study included 114 hips of 110 patients who underwent hip arthroscopy for femoroacetabular impingement between September 2022 and September 2024. Patients received indomethacin or acemetacin for 3 weeks postoperatively. HO development was assessed radiologically using the Brooker classification. Functional outcomes and non-steroidal anti-inflammatory drug-related adverse events were recorded and compared. HO developed in 6 hips (5.3%): 4 in the indomethacin group (8%) and 2 in the acemetacin group (3.1%) (P = .402).
Source : Journal of Hip Preservation Surgery
On : 13-Feb-2026